A recent survey conducted by STEM/MARK for the Czech Association of Pharmaceutical Companies has shed light on Czech citizens’ perspectives regarding drug prices and production. The survey indicated that over 58 percent of respondents expressed a willingness to pay higher drug prices if pharmaceutical production were relocated to Europe. Among senior citizens, this figure increased to over 70 percent. However, opinions differed on who should bear the cost of such a move, with suggestions ranging from pharmaceutical companies, the European Union (EU), or the state.

The survey, which took place in late April, also revealed that nearly all respondents had encountered drug shortages. However, most cases were resolved by pharmacists ordering the drug or patients using an equivalent product from another manufacturer. According to Filip Vrubel, the executive director of the Czech Association of Pharmaceutical Companies, the drug was completely unavailable in only 12 percent of instances.

One notable finding from the survey was a lack of understanding among Czech citizens regarding drug prices and the factors influencing them. A significant 92 percent of respondents did not know how drug prices are determined, while only 14 percent were aware that the government regulates the prices of prescription drugs. Furthermore, there was a misconception among many respondents that insurance covers the cost of over-the-counter drugs and dietary supplements, when in reality, insurance companies can only contribute to the cost from prevention funds.

The survey also touched upon the issue of drug shortages. When asked about the causes, 32 percent of respondents blamed increased demand, 16 percent pointed fingers at pharmaceutical companies, and 14 percent criticized the state for insufficient drug procurement.

These survey results highlight the complex and nuanced perspectives of Czech citizens when it comes to drug prices and production. While a majority expressed a willingness to pay more for locally produced drugs, opinions varied on who should shoulder the financial burden. Additionally, the survey underscored the need for greater education and transparency regarding drug pricing mechanisms and the role of insurance coverage.

Article by Prague Forum